Peptide–and protein–nanoparticle conjugates have emerged as powerful tools for
biomedical applications, enabling the treatment, diagnosis, and prevention of disease. In …

Tumor cells overexpress surface markers which are absent from normal cells. These tumor-
restricted antigenic signatures are a fundamental basis for distinguishing on-target from off …

The chemotherapy of glioblastoma is severely hindered by the immunosuppressive tumor
microenvironment, especially the tumor growth factor β (TGF‐β), an immunosuppressive …

The poor prognosis and rapid recurrence of glioblastoma (GB) are associated to its fast-
growing process and invasive nature, which make difficult the complete removal of the …

Based on the overexpression of specific receptors on tumor cells, active targeting
nanomedicines have been developed with the ability to efficiently deliver imaging agents in …

Glioma is a highly challenging human malignancy as drugs typically exhibit a low blood-
brain barrier (BBB) permeability as well as poor glioma selectivity and penetration. Here, we …

The advancement of tissue and cell-specific drug delivery systems is a key to precision
cancer therapy. Peptides, with easy synthesis, low immunogenicity and biological functions …

Cell-penetrating peptides (CPPs) have become a novel drug delivery system due to their
distinct advantages, including high cell transmembrane potency and ability to carry cargo …

Cancer has become one of the leading causes of mortality globally. The major challenges of
conventional cancer therapy are the failure of most chemotherapeutic agents to accumulate …

Delivery of small interfering RNA (siRNA) to suppress glioblastoma growth is a hurdle due to
the critical obstacles of the blood-brain barrier and the siRNA properties of such as high …